Peifer Christian, Kinkel Katrin, Abadleh Mohammed, Schollmeyer Dieter, Laufer Stefan
Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, Eberhard-Karls-University Tübingen, Auf der Morgenstelle 8/B, D-72076 Tübingen, Germany.
J Med Chem. 2007 Mar 22;50(6):1213-21. doi: 10.1021/jm061097o. Epub 2007 Feb 27.
In this study we describe the design, synthesis, and biological evaluation of 3-(4-fluorophenyl)-4-pyridin-4-ylquinoline-2(1H)-one (5) as a new inhibitor of MAPK with a p38alphaMAPK IC50 of 1.8 muM. By keeping the common vicinal pyridine/4-F-phenyl pharmacophore, such as in prototypical imidazole 20 or isoxazole 13 but in 5 connected to the six-membered quinoline core, we were particularly interested in comparing biological activity, details of molecular geometry, and different binding modes of these compounds. Compounds 20 and 13 were active both in the p38alpha- and JNK3-assay, whereas 5 was selective for p38alpha, with no JNK3 inhibition. By comparing the X-ray structures of the compounds, we found a significantly larger distance between the pyridine and the 4-F-phenyl moiety in five-membered core structures relevant for ligand-protein interactions. Molecular modeling studies support the results based on differences in the ATP pockets of p38alpha and JNK3. Because most five-membered core based p38alpha inhibitors show also activity for JNK3, compound 5 is an interesting lead for selective p38alpha inhibitors.
在本研究中,我们描述了3-(4-氟苯基)-4-吡啶-4-基喹啉-2(1H)-酮(5)作为一种新的丝裂原活化蛋白激酶(MAPK)抑制剂的设计、合成及生物学评价,其对p38α MAPK的半数抑制浓度(IC50)为1.8 μM。通过保留常见的邻位吡啶/4-氟苯基药效团,如在原型咪唑20或异恶唑13中,但在化合物5中与六元喹啉核心相连,我们特别感兴趣于比较这些化合物的生物活性、分子几何细节和不同的结合模式。化合物20和13在p38α和JNK3检测中均有活性,而化合物5对p38α具有选择性,无JNK3抑制作用。通过比较这些化合物的X射线结构,我们发现在与配体-蛋白质相互作用相关的五元核心结构中,吡啶和4-氟苯基部分之间的距离明显更大。分子模拟研究基于p38α和JNK3的ATP口袋差异支持了该结果。由于大多数基于五元核心的p38α抑制剂对JNK3也有活性,化合物5是选择性p38α抑制剂的一个有趣先导化合物。